The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1411571
Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs chemotherapy alone for unresectable advanced or metastatic Gastric or Gastroesophageal Junction Cancer in China
Provisionally accepted- 1 Department of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
- 2 Department of Clinical Pharmacy, The First People’s Hospital of Yunnan Province, Kunming, Yunnan Province, China
Background The Chinese Society of Clinical Oncology (CSCO) has recommended sintilimab plus chemotherapy (SINT+Chemo) as a standard first-line therapy for advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC), based on the proven effectiveness and safety in the ORINT-16 trail. Its cost-effectiveness, however, remains to be evaluated. Methods We established a partitioned survival approach (PartSA) model with a 10-year time horizon to determine whether SINT+Chemo (vs chemotherapy) was more cost-effective as a first-line treatment for unresectable advanced or metastatic GC/GEJC. Survival data was generated from the ORIENT-16 trail. Cost calculation was limited to direct medical costs. Database of Hunan Public Resources Trading Service Platform was used as the source for obtaining drug prices. Other cost and utility values were gathered from established literature. Incremental cost-effectiveness ratio (ICER) was the primary output. Additionally, we conducted sensitivity analysis, subgroup analysis, and scenario analysis. Results In the base-case analysis, group SINT+Chemo showed an increase in utility value by 0.32 quality-adjusted life-years (QALYs) at an extra cost of $7988.43, resulting in an ICER of $25239.29/QALY, below the Chinese cost-effective willingness-to-pay(WTP) threshold of $38223.34. Upon further subgroup analysis according to patients’ programmed death 1 ligand (PD-L1) combined positive score (CPS) , the ICERs were $26341.01/ QALY for patients highly expressing PD-L1 (CPS ≥ 5) and $17658.26/QALY for patients lowly expressing PD-L1 (CPS < 5). Based on the sensitivity analysis, we found the PFS utility was the parameter that had the most significant impact on the model's outcomes. Moreover, in scenario analysis, the results remained consistent despite variations in the model's time frame. Conclusion In China, SINT+Chemo is a more cost-effective option (vs chemotherapy) as a first-line therapy for unresectable advanced or metastatic GC/GEJC, irrespective of PD-L1 expression levels.
Keywords: Cost-Effectiveness, Sintilimab, gastric cancer, Gastroesophageal junction cancer, partitioned survival approach
Received: 03 Apr 2024; Accepted: 26 Aug 2024.
Copyright: © 2024 Xiang, Ma, Fu and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yong Pan, Department of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.